Vu1 (VUOC) 10-Q 14 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 14, 2014
Document and Entity Information:	'	'
Entity Registrant Name	'Vu1 CORP	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Entity Central Index Key	'0000906448	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	10,956,097
Entity Filer Category	'Smaller Reporting Company	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash	$2,344	$92,795
Prepaid expenses	7,800	190,005
Total current assets	10,144	282,800
Non-current assets	'	'
Equipment and construction in process, net of accumulated depreciation of $8,061 and $3,402	102,506	30,614
Total assets	112,650	313,414
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable	1,376,698	1,148,368
Accrued payroll	192,725	192,725
Accrued interest	475,814	324,531
Loans payable	100,000	100,000
Convertible debentures	3,788,325	3,905,975
Liabilities of Sendio	555,454	555,454
Total current liabilities	6,489,016	6,227,053
Total liabilities	6,489,016	6,227,053
Stockholders' deficit	'	'
Preferred stock, $1.00 par value; 10,000,000 shares authorized; no shares issued and outstanding	'	'
Common stock, no par value; 90,000,000 shares authorized; 11,573,448 and 10,576,097 shares issued and outstanding, respectively	83,807,106	82,609,032
Accumulated deficit	-90,087,417	-88,426,616
Total Vu1 Corporation's stockholders' deficit	-6,280,311	-5,817,584
Non-controlling interest	-96,055	-96,055
Total stockholders' deficit	-6,376,366	-5,913,639
Total liabilities and stockholders' deficit	$112,650	$313,414

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICAL (USD $)	Jun. 30, 2014	Dec. 31, 2013
CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICAL	'	'
Accumulated depreciation	$8,061	$3,402
Preferred stock par value	$1	$1
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	'	'
Preferred stock shares outstanding	'	'
Common stock par value	'	'
Common stock shares authorized	90,000,000	90,000,000
Common stock shares issued	11,573,448	10,576,097
Common stock shares outstanding	11,573,448	10,576,097

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Operating expenses	'	'	'	'
Research and development	$268,590	$126,009	$558,087	$261,607
General and administrative	291,580	356,981	586,934	1,107,484
Marketing	65,933	105,716	133,034	154,140
Total operating expenses	626,103	588,706	1,278,055	1,523,231
Loss from operations	-626,103	-588,706	-1,278,055	-1,523,231
Other income (expense)	'	'	'	'
Interest expense	-231,871	-518,325	-382,746	-888,699
Loss on conversion of debt	'	-29,020	'	-1,114,764
Total other income (expense)	-231,871	-547,345	-382,746	-2,003,463
Loss before provision for income taxes	-857,974	-1,136,051	-1,660,801	-3,526,694
Provision for income taxes	'	'	'	'
Net loss	($857,974)	($1,136,051)	($1,660,801)	($3,526,694)
Basic Loss per share	($0.08)	($0.13)	($0.16)	($0.39)
Diluted Loss per share	($0.08)	($0.13)	($0.16)	($0.39)
Basic Weighted average shares outstanding	10,809,651	8,894,847	10,579,399	9,020,447
Diluted Weighted average shares outstanding	10,809,651	8,894,847	10,579,399	9,020,447

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash Flows From Operating Activities	'	'
Net loss	($1,660,801)	($3,526,694)
Adjustments to reconcile net loss to net cash flows from operating activities:	'	'
Depreciation	4,659	'
Share-based compensation	245,553	783,509
Amortization of beneficial conversion feature	95,671	'
Amortization of discount on long-term convertible notes	'	571,254
Amortization of loan costs	'	118,500
Amortization of prepaid interest	'	25,000
Loss on extinguishment of debt	'	1,114,764
Changes in assets and liabilities:	'	'
Change in prepaid expenses	182,205	-164,488
Change in accounts payable	228,330	301,610
Change in accrued interest	285,485	'
Net cash flows from operating activities	-618,898	-776,545
Cash flows from investing activity:	'	'
Purchase of equipment	-76,553	-34,015
Net cash flows from investing activity	-76,553	-34,015
Cash flows from financing activities:	'	'
Net proceeds from sales of common stock and warrants	605,000	793,465
Proceeds from convertible bridge loan	132,876	100,000
Payments of judgment	-132,876	'
Net cash flows from financing activities	605,000	893,465
Net change in cash	-90,451	82,905
Cash, beginning of period	92,795	328,188
Cash, end of period	2,344	411,093
Supplemental Cash Flow Information:	'	'
Cash paid for interest	14,619	'
Supplemental Noncash Investing and Financing Activities:	'	'
Issuance of common stock for interest	117,650	'
Conversion of bridge loan and interest to stock	134,200	'
Conversion of debenture for stock	'	123,538
Issuance of common stock and warrants for note payable	'	110,000
Conversion of bridge loan and interest to stock and warrants	'	$368,162

Note_1_Business_and_Organizati

Note 1 - Business and Organization	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 1 - Business and Organization	'
	NOTE 1 - BUSINESS AND ORGANIZATION
	General
	All references in these consolidated financial statements to “we,” “us,” “our,” and the “Company” are to Vu1 Corporation, Sendio, s.r.o., our former Czech subsidiary, and Telisar Corporation, our inactive subsidiary unless otherwise noted or indicated by its context.
	We are focused on developing, manufacturing and selling a line of mercury free, energy efficient light bulbs based on our proprietary light-emitting technology. For the past several years, we have primarily focused on research and development efforts for our technology products and the related manufacturing processes.
	We have one inactive subsidiary, Telisar Corporation, a California corporation and 66.67% majority-owned subsidiary.

Note_2_Basis_of_Presentation_a

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies	'
	NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The consolidated unaudited financial statements included in this Form 10-Q have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, these financial statements do not include all of the disclosures required by U.S. generally accepted accounting principles for complete financial statements.  These consolidated unaudited interim financial statements should be read in conjunction with the audited financial statements for the fiscal year ended December 31, 2013 in our Annual Report on Form 10-K.  The financial information furnished herein reflects all adjustments consisting of normal, recurring adjustments which, in the opinion of management, are necessary for a fair presentation of our financial position, the results of operations and cash flows for the periods presented.  Operating results for the quarterly period ended June 30, 2014 are not necessarily indicative of results for future quarters or periods in the fiscal year ending December 31, 2014.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and all of its wholly-owned and controlled subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	For purposes of the statements of cash flows, we consider all investments purchased with original maturities of three months or less to be cash equivalents. At June 30, 2014 and December 31, 2013 we had no cash in excess of federal insurance limits.
	Loan Costs
	Loan costs are amortized to interest expense using the straight line method, which approximates the effective interest method, over the life of the related loan.
	Equipment
	Equipment is comprised of equipment used in the testing and development of the manufacturing process for our lighting products and is stated at cost. We provide for depreciation using the straight-line method over the estimated useful lives of three to five years. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains or losses on the sale of equipment are reflected in the statements of operations.
	Long-Lived Assets
	Long-lived assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
	Income Taxes
	We recognize the amount of income taxes payable or refundable for the current year and recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement amounts of certain assets and liabilities and their respective tax bases. Deferred tax assets and deferred tax liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled. A valuation allowance is required when it is more likely than not that we will not be able to realize all or a portion of our deferred tax assets. The fiscal years 2010 to 2013 remain open to examination to U.S. Federal authorities and other jurisdictions in the U.S. where we operate.
	We recognize the impact of an uncertain tax position in the consolidated financial statements of a tax position, if that position is more likely than not of being sustained upon examination, based on the technical merits of the position.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits, if and when required, as part of income tax expense in the consolidated statements of operations.
	Fair Value of Financial Instruments
	Financial instruments consist of loans payable and convertible debentures. The fair value of our loans payable are carried at historical cost; their respective estimated fair values approximate their carrying values due to the short term nature of these items.  We use level 3 inputs under the fair value hierarchy to estimate the fair value of these instruments. It is not practical to determine the fair value of our convertible debentures due to the unique terms and embedded financial instruments.
	Derivative financial instruments, as defined in ASC 815 “Accounting for Derivative Financial Instruments and Hedging Activities” consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g., interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks.
	Fair Value Measurements
	ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. This hierarchy prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Significant fair value measurements resulted from the application of ASC 815 to our convertible promissory note and warrant financing arrangements and ASC 718-10 for our share-based payment arrangements.
	Non-Controlling Interest
	Non-controlling interest represents the equity of the 33.3% non-controlling shareholders of Telisar Corporation.  The subsidiary had no operations for all periods presented.
	Revenue Recognition
	Revenues are recognized when (a) persuasive evidence of an arrangement exists, (b) delivery has occurred and no significant obligations remain, (c) the fee is fixed or determinable and (d) collection is determined to be probable.
	Research and Development Costs
	For financial reporting purposes, all costs of research and development activities performed internally or on a contract basis are expensed as incurred. For the three and  six months ended June 30, 2014 and 2013, research and development expenses were comprised primarily of technical consulting expenses, travel, materials and operational costs related to the development of the production line.
	Share-Based Payments
	We account for share-based compensation expense to reflect the fair value of share-based awards measured at the grant date.  This expense is recognized over the requisite service period and is adjusted each period for anticipated forfeitures. We estimate the fair value of each share-based award on the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model incorporates assumptions as to stock price volatility, the expected life of options, a risk-free interest rate and dividend yield.
	Loss Per Share
	We calculate basic loss per share by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.
	The following potentially dilutive shares of common stock are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive:
		Three Months Ended June 30,		Six Months Ended June 30,
		2014	2013	2014	2013
	Warrants	5,377,228	4,187,052	5,377,228	4,187,052
	Convertible debt	1,368,805	1,152,223	1,368,805	1,152,223
	Stock options	484,936	626,870	484,936	626,870
	Unvested stock	-	39,231	-	39,231
	Total potentially dilutive securities	7,230,969	6,005,376	7,230,969	6,005,376

Note_3_Going_Concern_Matters

Note 3 - Going Concern Matters	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 3 - Going Concern Matters	'
	NOTE 3 - GOING CONCERN MATTERS
	The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate our continuation as a going concern. During the six months ended June 30, 2014 we had no revenues, incurred a net loss of $1.65 million(1,660,801), and had negative cash flows from operations of $0.62 million (618,898). In addition, we had an accumulated deficit of $90.08 million (90,087,417) at June 30, 2014. In addition, we are in default on approximately $1.45 million1,450,000 of our convertible debt and notes payable plus related accrued interest. These factors raise substantial doubt about our ability to continue as a going concern.
	Recovery of our assets is dependent upon future events, the outcome of which is indeterminable. Our attainment of profitable operations is dependent upon our obtaining adequate debt or equity financing, developing products for commercial sale, and achieving a level of sales adequate to support our cost structure. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should we be unable to continue in existence.
	Our efforts to raise additional funds will continue during fiscal 2014 to fund our planned operations and research and development activities, through one or more debt or equity financings.  Subsequent to June 30, 2014, we raised gross proceeds of $135,000 in a private placement of our common stock and warrants to accredited investors.  See Note 8.

Note_4_Commitments_and_Conting

Note 4 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 4 - Commitments and Contingencies	'
	NOTE 4 - COMMITMENTS AND CONTINGENCIES
	Litigation
	On June 11, 2014, four holders of our Convertible Debentures totaling $705,900 in principal plus accrued interest of $198,696 as of June 30, 2014 filed a motion seeking summary judgment with the Supreme Court of the State of New York.  The case was heard on July 31, 2014 and the court granted their request and issued a judgment in their favor for the full amount of principal and interest, plus certain expenses.  We are working with their attorney to attempt to find a settlement agreeable to both parties.
	Judgment Payable
	On April 10, 2014 we received notice from one of the holders of our Convertible Debentures regarding a judgment they obtained on March 6, 2014 in the amount of $132,876, including principal of $117,500, accrued interest of $14,619 and costs of $605 as of that date. The judgment bore interest at a 9% rate until paid in full and is secured by the assets of the Company. On May 12, 2014 the judgment was paid in full.
	Lease Agreement
	On January 28, 2014 we entered into a lease agreement for approximately 4,600 square feet of office and light industrial space located in Berkeley, California in the United States.  We utilize the facility for our research and development activities and as our corporate headquarters.
	The lease term is for two years effective from February 1, 2014 and terminates on January 31, 2016. Our lease obligations are $30,000, $60,000 and $5,000 for the years ended December 31, 2014, 2015 and 2016, respectively.
	The Company is also responsible for certain insurance, utilities, maintenance and other costs as described in the lease.
	Liabilities of Sendio
	In September 2007, we formed Sendio, s.r.o. (“Sendio”) in the Czech Republic as a wholly-owned subsidiary for the purpose of operating a research and development and pilot manufacturing facility. On February 13, 2012, Sendio filed a petition of insolvency with the Regional Court in Olomouc, Czech Republic.  In March, 2012 the court determined that Sendio was insolvent, and control of the legal entity passed to a court appointed trustee. The trustee will oversee the orderly sale of the assets and use any proceeds to satisfy the liabilities of Sendio.  These liabilities have been recorded as a current liability on our balance sheet as of June 30, 2014 and December 31, 2013 under the caption “Liabilities of Sendio.”

Note_5_Convertible_Debentures

Note 5 - Convertible Debentures	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 5 - Convertible Debentures	'
	NOTE 5 – CONVERTIBLE DEBENTURES
	On June 22, 2011, pursuant to a Securities Purchase Agreement, dated as of June 16, 2011, with several institutional investors, we completed a private placement of our original issue discount convertible debentures (referred to as the convertible debentures), receiving gross proceeds of $3,500,000.  Each convertible debenture was issued at a price equal to 85% of its principal amount.  The convertible debentures matured on June 22, 2013, two years after the date of their issuance and did not bear regularly scheduled interest.  Investors may convert their convertible debentures into shares of our common stock at any time and from time to time on or before the maturity date, at a conversion price of $11.00 per share.
	The convertible debentures will mandatorily convert at our option into shares of our common stock at the conversion price, if the closing bid price for the common stock exceeds $30.00 per share for a period of 10 consecutive trading days, provided that such underlying shares have been fully registered for resale with the U.S. Securities and Exchange Commission (SEC).
	The convertible debentures are unsecured, general obligations of our company, and rank pari passu with our other unsecured and unsubordinated liabilities.  The convertible debentures are not redeemable or subject to voluntary prepayment by us prior to maturity.  The convertible debentures were identical for all of the investors except for principal amount.
	The investors agreed not to convert their convertible debentures or exercise their warrants, and we will not be permitted to require a mandatory conversion, to the extent such conversion, exercise or issuance would result in beneficial ownership of more than 4.99% of our outstanding shares at such time.
	Events of default under the convertible debentures include:
	•              failure to pay principal or any liquidated damages on any convertible debenture when due;
	•              failure to perform other covenants under the convertible debentures that is not cured five trading days after notice by holders;
	•              default under the other financing documents, subject to any grace or cure period provided in the applicable agreement, document or instrument;
	•              certain events of bankruptcy or insolvency of our company or any significant subsidiary.  The lender has waived this event of default with respect to the insolvency of Sendio.
	•              any default by our company or any subsidiary under any instrument in excess of $150,000 that results in such obligation becoming due and payable prior to maturity;
	•              we become party to a change of control transaction, or dispose of greater than 50% of our assets; and
	•              failure to deliver common stock certificates to a holder prior to the tenth trading day after a convertible debenture conversion date.
	Upon an event of default, the outstanding principal amount of the convertible debentures, plus a default premium, shall become immediately due and payable to the holders of the convertible debentures.
	The convertible debentures contain various covenants that limit our ability to:
	•              incur additional indebtedness, other than permitted indebtedness as defined in the convertible debenture;
	•              incur specified liens, other than permitted liens as defined in the convertible debenture;
	•              amend our certificate of incorporation or by-laws in a material adverse manner to the holders; and
	•              repay or repurchase more than a de minimus number of shares of our common stock.
	As part of the financing, we also agreed not to undertake a reverse or forward stock split or reclassification of our common stock until the one-year anniversary of the closing date, except with the consent of a majority in interest of the holders or in connection with an up-listing of our common stock onto a trading market other than the OTC Bulletin Board.
	We also issued to the investors five-year warrants to purchase up to 187,175 shares of our common stock at an exercise price of $13.00 per share.  The warrants may be exercised on a cashless basis at any time after the earlier of (i) one year after the date of their issuance or (ii) the completion of the applicable holding period required by Rule 144 in the event the underlying shares have not been fully registered for resale with the SEC.  The warrants are not callable.  Neither the warrants nor the convertible debentures contain a provision for anti-dilution adjustments in the event of a subsequent equity financing at a price less than the respective warrant exercise price or convertible debenture conversion price.
	Pursuant to a Registration Rights Agreement, dated as of June 16, 2011, with the investors, we agreed to file a shelf registration statement covering the resale of the shares of common stock issuable upon the conversion of the convertible debentures and exercise of the warrants within 30 days after the closing, use our best efforts to cause the shelf registration statement to be declared effective within 90 days after the closing (or 120 days in the event of a “full review” by the SEC), and keep the shelf registration statement effective until the underlying shares have been sold or may be sold without volume or manner of sale restrictions pursuant to Rule 144 under the Securities Act of 1933 and if we are unable to comply with this covenant, we will be required to pay liquidated damages to the investors in the amount of 1.5% of the investors’ purchase price per month during such non-compliance (capped at a maximum of 10% of the purchase price), with such liquidated damages payable in cash.  We filed the registration statement on July 15, 2011 and it was declared effective on July 26, 2011.  We evaluated any liability under the registration rights agreement at June 30, 2014 and determined no accrual was necessary.
	Effective June 22, 2013, we entered into a letter agreement with holders of $2,553,000 in principal amount of the Debentures.  The maturity date of these Debentures was extended to June 23, 2014 and the conversion price was reduced from $11.00 to $2.50 per share.  In addition, these Debentures will bear interest at an annual rate of 10% per annum, payable in equal installments on the six month and one year anniversary of the letter agreement.  On June 23, 2014 we did not make the required payment of principal payment to the holders of these amended Debentures.  As a result, an additional principal amount of $200,000 plus accrued interest is in default as of that date.
	On June 20, 2014, we entered into a letter agreement with a Debenture holder of the original principal sum of $2,353,000.  Pursuant to the letter agreement, the Company and the holder agreed to extend the maturity date of the Debenture to June 22, 2015 and reduce the conversion price under the Debenture to $2.00 per share from the current $2.50 per share.  Additionally, we issued 125,160 shares of our common stock to the holder in payment of accrued, unpaid interest of $117,650 under the Debenture for the period from December 23, 2013 to June 22, 2014, which shares were valued at the closing price of $0.94 per share on the date of the agreement.
	On June 22, 2013, we did not make the required payment on the remaining principal amount of the Debentures of described above, which constituted an event of default under the terms of the remaining original Debentures.  The Company is also liable for all other amounts, costs, expenses and liquidated damages due in respect of those Debentures.  Additionally, the remaining original Debentures will bear default interest at a rate of 18% per annum. As a result of the Debentures being past due, the investors may at any time exercise their remedies under the terms of the Debentures.  On June 11, 2014, four holders of our Convertible Debentures totaling $705,900 in principal plus accrued interest of $198,696 as of June 30, 2014 filed a motion seeking summary judgment with the Supreme Court of the State of New York as discussed in Note 4.
	The carrying value at June 30, 2014 and December 31, 2013 of the convertible debentures is as follows:
		30-Jun-14	31-Dec-13
	Debentures Due June 22, 2013, in default at June 30, 2014, interest at 18%	$             1,435,325	$            1,352,975
	Debentures Due June 23, 2015, interest at 10%	2,353,000	2,553,000
	Carrying value	$             3,788,325	$            3,905,975
	Interest expense related to the convertible debentures is as follows:
		Three Months Ended June 30,		Six Months Ended June 30,
		2014	2013	2014	2013
	Amortization of original issue discount	$             -	$        75,354	$                 -	$     155,443
	Amortization of beneficial conversion feature and warrant allocation	-	206,320	-	415,811
	Amortization of loan costs	-	54,308	-	104,392
	Penalty interest	-	144,121	-	144,121
	Stated interest payable in cash	107,574	11,282	231,449	11,282
		$  107,574	$     491,385	$      231,449	$       831,049

Note_6_Loans_Payable

Note 6 - Loans Payable	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 6 - Loans Payable	'
	NOTE 6 – LOANS PAYABLE
	Loans Payable
	On December 20, 2012, we received gross proceeds of $100,000 pursuant to the terms of a Loan Agreement dated December 20, 2012.  The loan is secured by a deed of assignment for certain future inventory and proceeds from the sale of that inventory as described in the deed of assignment.  The loan was payable on June 23, 2013, six months from the date of the agreement.  We recognized $54,300 and $23,514 of interest expense and $0 and $14,108 for loan cost amortization within interest expense for the six months ended June 30, 2014 and 2013, respectively.
	On June 23, 2013 we did not repay the loan and it is in default.  As a result of the default, the interest rate on the loan is 109.5% per annum from the date of default.
	Total principal payments for future years for the Convertible Debentures described in Note 5 and the Loans Payable are as follows as of June 30, 2014:
		30-Jun-14
	2014	3,888,325
		$                  3,888,325
	On May 9, 2014 we issued an unsecured Convertible Promissory Note for cash to an accredited investor in the amount of $132,876.  The note bears interest at an annual rate of 7% per year, payable on the six month and one year anniversary of the note. The interest is payable at the option of the Company in either cash or shares of common stock at the market price on the interest payment dates as defined in the note. The note is convertible at any time at the option of the holder at a rate of $0.50 per share into 265,751 shares of our common stock.  We evaluated the Note and determined it had a beneficial conversion feature due to the conversion price being lower than the market price of our common stock of $0.86 per share on the date of issuance.  Accordingly, we recognized a discount related to the beneficial conversion feature associated with the Note in the amount of $95,671.
	On June 30, 2014 the holder of the note converted the principal amount by its terms into 265,751 shares of common stock.  In addition, the Company issued 1,440 shares of common stock related to the accrued interest of $1,325 based on the market price on the date of conversion of $0.92 per share.
	We recognized interest expense, comprised of $1,325 related to the stated interest rate of the note and $95,671 related to the beneficial conversion feature for the three and six months ended June 30, 2014.
	The proceeds from the Convertible Promissory Note discussed above were used to pay the judgment payable in full as discussed in Note 4.

Note_7_Stockholders_Equity

Note 7 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 7 - Stockholders' Equity	'
	NOTE 7 – STOCKHOLDERS’ EQUITY
	Preferred Stock
	Our Amended and Restated Articles of Incorporation allow us to issue up to 10,000,000 shares of preferred stock without further stockholder approval and upon such terms and conditions, and having such rights, preferences, privileges, and restrictions as the Board of Directors may determine.  No preferred shares are currently issued and outstanding.
	Common Stock
	2014 Unit Offerings
	During the six months ended June 30, 2014 we received gross proceeds of $605,000 from accredited investors at a price of $1.00 per unit and issued 605,000 shares of common stock and two-year warrants to purchase 605,000 shares of common stock at an exercise price of $1.25 per share.
	The net proceeds of $605,000 were allocated based on the relative fair values of the common stock and the warrants on the dates of issuance.  The amount allocated to the fair value of the warrants was $160,983 and the balance of the proceeds of $444,017 was allocated to the common stock.  The fair value of the warrants issued was computed using the Black Scholes Option Pricing model using the following assumptions – expected life – 2 years, risk free interest rate – 0.31% to 0.47%, volatility – 79.0% to 97.4%, and an expected dividend rate of 0%.
	Issuances of common stock
	On June 30, 2014 we issued 267,191 shares to an accredited investor upon the conversion of a Convertible Promissory Note as discussed in Note 6.
	On June 22, 2014 we issued 125,160 shares of the Company's common stock to the holder in payment of accrued, unpaid interest under the Debenture for the period from December 23, 2013 to June 22, 2014.
	During the six months ended June 30, 2014 we issued 605,000 shares of common stock in our unit offerings described above.
	Stock and Stock Options issued and exercised pursuant to the 2007 Stock Incentive Plan
	On August 26, 2013 the board of directors increased the number of shares authorized for issuance under the 2007 Stock Incentive Plan (the “Plan”) by 1,500,000 shares to a total of 2,500,000 shares.  The increase in shares is subject to shareholder approval of the amendment to the Plan.
	Stock issuances
	There were no issuances of stock from the Plan for the six months ended June 30, 2014.
	We recognized a total of $207,587 and $362,315 of compensation expense related to restricted stock issuances as general and administrative and research and development expenses for the six months ended June 30, 2014 and 2013, respectively.
	At June 30, 2014 there is no unrecognized compensation expense related to stock issued from the Plan.
	Stock Option issuances
	On February 11, 2014 we issued a five-year option to purchase 13,158 shares of common stock from the Plan at an exercise price of $1.14 per share to a consultant for services.  The fair value of the option granted of $9,558 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 5 years, risk free interest rate – 1.54%, volatility – 79.0%, and an expected dividend rate of 0%.
	On May 13, 2014 we issued options to purchase 29,412 shares of common stock at an exercise price of $0.85 per share based on the closing market price of our common stock as of that date to a consultant for services. The fair value of the option granted of $16,489 was calculated using the Black-Scholes option valuation model with the following assumptions – expected life – 5 years, risk free interest rate – 1.62%, volatility – 82.8%, and an expected dividend rate of 0%.
	We recognized compensation expense of $37,966 and $334,632 related to the vested portion of stock options based on their estimated grant date fair value as research and development expense or general and administrative expense based on the specific recipient of the award for the six months ended June 30, 2014 and 2013, respectively.
	At June 30, 2014, we have unrecognized compensation expense related to stock options of $14,905, of which we anticipate $13,024 will be recognized through December 31, 2014 and $1,881 will be recognized in 2015.
	During the six months ended June 30, 2014, options to purchase 152,722 shares of common stock at a weighted average exercise price of $10.42 per share expired unexercised.
	Warrants
	During the six months ended June 30, 2014 we issued two-year warrants to purchase 605,000 shares of common stock at an exercise price of $1.25 per share in our unit offering described above.
	A summary of our outstanding warrants at June 30, 2014 is as follows:
			Weighted-Average
	Exercise	Warrants	Remaining Contractual	Number
	Price	Outstanding	Life (Years)	Exercisable
	$1.25	1,255,000	1.8	1,255,000
	$1.50	2,909,360	1.4	2,909,360
	$2.00	580,667	2.2	580,667
	$9.00	262,750	1.9	262,750
	$11.00	156,071	1.6	156,071
	$13.00	213,380	2.2	213,380
		5,377,228	1.6	5,377,228

Note_8_Subsequent_Events

Note 8 - Subsequent Events	6 Months Ended
	Jun. 30, 2014
Notes	'
Note 8 - Subsequent Events	'
	NOTE 8 – SUBSEQUENT EVENTS
	From July 1 to July 10, 2014 we received gross proceeds of $75,000 from accredited investors at a price of $1.00 per unit and issued 75,000 shares of common stock and two-year warrants to purchase 75,000 shares of common stock at an exercise price of $1.25 per share.
	From August 4 through August 8, 2014, we received gross proceeds of $60,000 from accredited investors at a price of $0.50 per unit and issued 120,000 shares of common stock and two-year warrants to purchase 120,000 shares of common stock at an exercise price of $0.75 per share.
	In July, 2014 the board of directors approved the issuance of up to 149,999 three-year options to purchase common stock to four of our engineering consultants.  The options will vest immediately, and will be issued at the market price on the date of completion of certain objectives.

Note_2_Basis_of_Presentation_a1

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated unaudited financial statements included in this Form 10-Q have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, these financial statements do not include all of the disclosures required by U.S. generally accepted accounting principles for complete financial statements.  These consolidated unaudited interim financial statements should be read in conjunction with the audited financial statements for the fiscal year ended December 31, 2013 in our Annual Report on Form 10-K.  The financial information furnished herein reflects all adjustments consisting of normal, recurring adjustments which, in the opinion of management, are necessary for a fair presentation of our financial position, the results of operations and cash flows for the periods presented.  Operating results for the quarterly period ended June 30, 2014 are not necessarily indicative of results for future quarters or periods in the fiscal year ending December 31, 2014.

Note_2_Basis_of_Presentation_a2

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and all of its wholly-owned and controlled subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

Note_2_Basis_of_Presentation_a3

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Use of Estimates (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Note_2_Basis_of_Presentation_a4

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For purposes of the statements of cash flows, we consider all investments purchased with original maturities of three months or less to be cash equivalents. At June 30, 2014 and December 31, 2013 we had no cash in excess of federal insurance limits.

Note_2_Basis_of_Presentation_a5

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Loan Costs (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Loan Costs	'
	Loan Costs
	Loan costs are amortized to interest expense using the straight line method, which approximates the effective interest method, over the life of the related loan.

Note_2_Basis_of_Presentation_a6

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Equipment (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Equipment	'
	Equipment
	Equipment is comprised of equipment used in the testing and development of the manufacturing process for our lighting products and is stated at cost. We provide for depreciation using the straight-line method over the estimated useful lives of three to five years. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains or losses on the sale of equipment are reflected in the statements of operations.

Note_2_Basis_of_Presentation_a7

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Long-lived Assets (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Long-lived Assets	'
	Long-Lived Assets
	Long-lived assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount that the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Note_2_Basis_of_Presentation_a8

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Income Taxes (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Income Taxes	'
	Income Taxes
	We recognize the amount of income taxes payable or refundable for the current year and recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement amounts of certain assets and liabilities and their respective tax bases. Deferred tax assets and deferred tax liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled. A valuation allowance is required when it is more likely than not that we will not be able to realize all or a portion of our deferred tax assets. The fiscal years 2010 to 2013 remain open to examination to U.S. Federal authorities and other jurisdictions in the U.S. where we operate.
	We recognize the impact of an uncertain tax position in the consolidated financial statements of a tax position, if that position is more likely than not of being sustained upon examination, based on the technical merits of the position.  Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits, if and when required, as part of income tax expense in the consolidated statements of operations.

Note_2_Basis_of_Presentation_a9

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Financial instruments consist of loans payable and convertible debentures. The fair value of our loans payable are carried at historical cost; their respective estimated fair values approximate their carrying values due to the short term nature of these items.  We use level 3 inputs under the fair value hierarchy to estimate the fair value of these instruments. It is not practical to determine the fair value of our convertible debentures due to the unique terms and embedded financial instruments.
	Derivative financial instruments, as defined in ASC 815 “Accounting for Derivative Financial Instruments and Hedging Activities” consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g., interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks.

Recovered_Sheet1

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Fair Value Measurements (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Fair Value Measurements	'
	Fair Value Measurements
	ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. This hierarchy prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Significant fair value measurements resulted from the application of ASC 815 to our convertible promissory note and warrant financing arrangements and ASC 718-10 for our share-based payment arrangements.

Recovered_Sheet2

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Non-controlling Interest (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Non-controlling Interest	'
	Non-Controlling Interest
	Non-controlling interest represents the equity of the 33.3% non-controlling shareholders of Telisar Corporation.  The subsidiary had no operations for all periods presented.

Recovered_Sheet3

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Revenue Recognition (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Revenue Recognition	'
	Revenue Recognition
	Revenues are recognized when (a) persuasive evidence of an arrangement exists, (b) delivery has occurred and no significant obligations remain, (c) the fee is fixed or determinable and (d) collection is determined to be probable.

Recovered_Sheet4

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Research and Development Costs (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Research and Development Costs	'
	Research and Development Costs
	For financial reporting purposes, all costs of research and development activities performed internally or on a contract basis are expensed as incurred. For the three and  six months ended June 30, 2014 and 2013, research and development expenses were comprised primarily of technical consulting expenses, travel, materials and operational costs related to the development of the production line.

Recovered_Sheet5

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Share-based Payments (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Share-based Payments	'
	Share-Based Payments
	We account for share-based compensation expense to reflect the fair value of share-based awards measured at the grant date.  This expense is recognized over the requisite service period and is adjusted each period for anticipated forfeitures. We estimate the fair value of each share-based award on the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model incorporates assumptions as to stock price volatility, the expected life of options, a risk-free interest rate and dividend yield.

Recovered_Sheet6

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Loss Per Share (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Loss Per Share	'
	Loss Per Share
	We calculate basic loss per share by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.
	The following potentially dilutive shares of common stock are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive:
		Three Months Ended June 30,		Six Months Ended June 30,
		2014	2013	2014	2013
	Warrants	5,377,228	4,187,052	5,377,228	4,187,052
	Convertible debt	1,368,805	1,152,223	1,368,805	1,152,223
	Stock options	484,936	626,870	484,936	626,870
	Unvested stock	-	39,231	-	39,231
	Total potentially dilutive securities	7,230,969	6,005,376	7,230,969	6,005,376

Recovered_Sheet7

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Loss Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
		Three Months Ended June 30,		Six Months Ended June 30,
		2014	2013	2014	2013
	Warrants	5,377,228	4,187,052	5,377,228	4,187,052
	Convertible debt	1,368,805	1,152,223	1,368,805	1,152,223
	Stock options	484,936	626,870	484,936	626,870
	Unvested stock	-	39,231	-	39,231
	Total potentially dilutive securities	7,230,969	6,005,376	7,230,969	6,005,376

Note_5_Convertible_Debentures_

Note 5 - Convertible Debentures: Schedule of Carrying Values of Convertible Debentures (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Carrying Values of Convertible Debentures	'
		30-Jun-14	31-Dec-13
	Debentures Due June 22, 2013, in default at June 30, 2014, interest at 18%	$             1,435,325	$            1,352,975
	Debentures Due June 23, 2015, interest at 10%	2,353,000	2,553,000
	Carrying value	$             3,788,325	$            3,905,975

Note_5_Convertible_Debentures_1

Note 5 - Convertible Debentures: Schedule Of Interest Expense Convertible Debentures (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule Of Interest Expense Convertible Debentures	'
		Three Months Ended June 30,		Six Months Ended June 30,
		2014	2013	2014	2013
	Amortization of original issue discount	$             -	$        75,354	$                 -	$     155,443
	Amortization of beneficial conversion feature and warrant allocation	-	206,320	-	415,811
	Amortization of loan costs	-	54,308	-	104,392
	Penalty interest	-	144,121	-	144,121
	Stated interest payable in cash	107,574	11,282	231,449	11,282
		$  107,574	$     491,385	$      231,449	$       831,049

Note_6_Loans_Payable_Schedule_

Note 6 - Loans Payable: Schedule of Maturities of Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Maturities of Long-Term Debt	'
		30-Jun-14
	2014	3,888,325
		$                  3,888,325

Note_7_Stockholders_Equity_Sch

Note 7 - Stockholders' Equity: Schedule of Outstanding Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Outstanding Warrants	'
			Weighted-Average
	Exercise	Warrants	Remaining Contractual	Number
	Price	Outstanding	Life (Years)	Exercisable
	$1.25	1,255,000	1.8	1,255,000
	$1.50	2,909,360	1.4	2,909,360
	$2.00	580,667	2.2	580,667
	$9.00	262,750	1.9	262,750
	$11.00	156,071	1.6	156,071
	$13.00	213,380	2.2	213,380
		5,377,228	1.6	5,377,228

Note_1_Business_and_Organizati1

Note 1 - Business and Organization (Details)	6 Months Ended
	Jun. 30, 2014
Details	'
Cumulative Percentage of Ownership	66.67%

Recovered_Sheet8

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Non-controlling Interest (Details)	Jun. 30, 2014
Details	'
Non-controlling Interest, Telisar Corporation	33.30%

Recovered_Sheet9

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Loss Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded From Computation of Earnings Per Share	7,230,969	6,005,376	7,230,969	6,005,376
Warrant	'	'	'	'
Antidilutive Securities Excluded From Computation of Earnings Per Share	5,377,228	4,187,052	5,377,228	4,187,052
Convertible Debt Securities	'	'	'	'
Antidilutive Securities Excluded From Computation of Earnings Per Share	1,368,805	1,152,223	1,368,805	1,152,223
EmployeestockoptionMember	'	'	'	'
Antidilutive Securities Excluded From Computation of Earnings Per Share	484,936	626,870	484,936	626,870
Unvested Stock	'	'	'	'
Antidilutive Securities Excluded From Computation of Earnings Per Share	'	39,231	'	39,231

Note_3_Going_Concern_Matters_D

Note 3 - Going Concern Matters (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Details	'	'	'	'	'
Net loss	($857,974)	($1,136,051)	($1,660,801)	($3,526,694)	'
Net cash flows from operating activities	'	'	-618,898	-776,545	'
Accumulated deficit	-90,087,417	'	-90,087,417	'	-88,426,616
Convertible Debt and Notes Payable in default	1,450,000	'	1,450,000	'	'
Proceeds raised by private placement of common stock	'	'	$135,000	'	'

Note_4_Commitments_and_Conting1

Note 4 - Commitments and Contingencies (Details) (USD $)	Jun. 30, 2014	Jun. 11, 2014
Details	'	'
Estimated Litigation Liability	'	$705,900
Judgment payable	132,876	'
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year	30,000	'
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two	60,000	'
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three	$5,000	'

Note_5_Convertible_Debentures_2

Note 5 - Convertible Debentures (Details) (ConvertibleDebenturesMember, USD $)	6 Months Ended
	Jun. 30, 2014
ConvertibleDebenturesMember	'
Proceeds from issuance of convertible notes and warrants	$3,500,000
Debenture Issue Price Percentage	85.00%
Conversion Price per Share	$11
Limit on Beneficial Ownership as a Percentage of Outstanding Shares	4.99%
Debt Securities Default Condition Monetary Limit	$150,000
Assets Disposal Percentage	50.00%
Warrants Issued in Conjunction with Convertible Debentures	187,175
Warrants Exercise Price	$13

Note_5_Convertible_Debentures_3

Note 5 - Convertible Debentures: Schedule of Carrying Values of Convertible Debentures (Details) (USD $)	Jun. 30, 2014		Dec. 31, 2013
Carrying value	$3,788,325		$3,905,975
Debentures due June 22, 2013	'		'
Face amount	1,435,325	[1]	1,352,975	[1]
Debentures due June 23, 2014	'		'
Face amount	$2,353,000	[2]	$2,553,000	[2]
[1]	Interest at 18%
[2]	Interest at 10%

Note_5_Convertible_Debentures_4

Note 5 - Convertible Debentures: Schedule Of Interest Expense Convertible Debentures (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Details	'	'	'	'
Amortization of original issue discount	'	$75,354	'	$155,443
Amortization of beneficial conversion feature and warrant allocation	'	206,320	'	415,811
Amortization of loan costs	'	54,308	'	104,392
Penalty interest	'	144,121	'	144,121
Stated interest payable in cash	107,574	11,282	231,449	11,282
Interest expense related to the convertible debentures	$107,574	$491,385	$231,449	$831,049

Note_6_Loans_Payable_December_

Note 6 - Loans Payable: December 20, 2012 (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 20, 2012
					December 20, 2012 Loan Payable	December 20, 2012 Loan Payable	December 20, 2012 Loan Payable
Proceeds From Loan Agreement	'	'	'	'	'	'	$100,000
Interest expense	231,871	518,325	382,746	888,699	54,300	23,514	'
Loan Cost Amortization	'	'	'	'	$0	$14,108	'
Default Interest rate	'	'	'	'	109.50%	'	'

Note_6_Loans_Payable_Schedule_1

Note 6 - Loans Payable: Schedule of Maturities of Long-Term Debt (Details) (USD $)	Jun. 30, 2014
Details	'
Convertible Debentures and Loan Payable	$3,888,325
Total convertible bridge loans	$3,888,325

Note_7_Stockholders_Equity_Det

Note 7 - Stockholders' Equity (Details) (USD $)	0 Months Ended		6 Months Ended
	Aug. 08, 2014	Jul. 10, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Aug. 26, 2013
						2007 Stock Incentive Plan
Preferred stock shares authorized	'	'	10,000,000	'	10,000,000	'
Net proceeds from sales of common stock and warrants	$60,000	$75,000	$605,000	$793,465	'	'
Common Stock Issued in Unit Offering	'	'	605,000	'	'	'
Common stock shares authorized	'	'	90,000,000	'	90,000,000	2,500,000

Note_7_Stockholders_Equity_Sto

Note 7 - Stockholders' Equity: Stock Issuances (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Details	'	'
Stock Issuance Compensation Expense	$207,587	$362,315

Note_7_Stockholders_Equity_Sto1

Note 7 - Stockholders' Equity: Stock Option issuances (Details) (USD $)	6 Months Ended		12 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2013	Feb. 20, 2013
					Board Members And Officer	Board Members And Officer
Issuance Of Stock Options	'	'	'	'	'	13,158
Exercise Price	'	'	'	'	$1.14	'
Fair Value Of Stock Options Issued	'	'	'	'	$9,558	'
Fair Value Assumptions, Expected Dividend Rate	'	'	'	'	0.00%	'
Compensation Expense Of Stock Options	37,966	334,632	'	'	'	'
Unrecognized Compensation Expense Related To Stock Options To Be Recognized	'	'	$1,881	$13,024	'	'
Expired options to purchase common stock	152,722	'	'	'	'	'

Note_7_Stockholders_Equity_War

Note 7 - Stockholders' Equity: Warrants (Details)	6 Months Ended
	Jun. 30, 2014
Details	'
Warrants Issued in Unit Offering	605,000

Note_7_Stockholders_Equity_Sch1

Note 7 - Stockholders' Equity: Schedule of Outstanding Warrants (Details)	Jun. 30, 2014
Warrant One	'
Exercise Price, Warrants	1.25
Warrants Outstanding	1,255,000
Weighted - Average Remaining Contractual Life (Years)	1.8
Warrants Exercisable	1,255,000
Warrant Two	'
Exercise Price, Warrants	1.5
Warrants Outstanding	2,909,360
Weighted - Average Remaining Contractual Life (Years)	1.4
Warrants Exercisable	2,909,360
Warrant Three	'
Exercise Price, Warrants	2
Warrants Outstanding	580,667
Weighted - Average Remaining Contractual Life (Years)	2.2
Warrants Exercisable	580,667
Warrant Four	'
Exercise Price, Warrants	9
Warrants Outstanding	262,750
Weighted - Average Remaining Contractual Life (Years)	1.9
Warrants Exercisable	262,750
Warrant Five	'
Exercise Price, Warrants	11
Warrants Outstanding	156,071
Weighted - Average Remaining Contractual Life (Years)	1.6
Warrants Exercisable	156,071
WarrantSixMember	'
Exercise Price, Warrants	13
Warrants Outstanding	213,380
Weighted - Average Remaining Contractual Life (Years)	2.2
Warrants Exercisable	213,380
Warrant	'
Warrants Outstanding	5,377,228
Weighted - Average Remaining Contractual Life (Years)	1.6
Warrants Exercisable	5,377,228

Note_8_Subsequent_Events_Detai

Note 8 - Subsequent Events (Details) (USD $)	0 Months Ended		1 Months Ended	6 Months Ended
	Aug. 08, 2014	Jul. 10, 2014	Jul. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
Details	'	'	'	'	'
Net proceeds from sales of common stock and warrants	$60,000	$75,000	'	$605,000	$793,465
Three year options to purchase common stock	'	'	149,999	'	'